🚀 VC round data is live in beta, check it out!
Starpharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Starpharma and similar public comparables like ProQR Therapeutics, Cereno Scientific, Searle Co., Sagimet Biosciences and more.
Starpharma Overview
About Starpharma
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
Founded
1997
HQ
Employees
40
Website
Sectors
Financials (LTM)
EV
$197M
Starpharma Financials
Starpharma reported last 12-month revenue of $10M and negative EBITDA of ($4M).
In the same LTM period, Starpharma generated $9M in gross profit, ($4M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
Starpharma P&L
In the most recent fiscal year, Starpharma reported revenue of $4M and EBITDA of ($6M).
Starpharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | $9M | XXX | $3M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | ($4M) | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (170%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (244%) | XXX | XXX | XXX |
| Net Profit | ($3M) | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | (35%) | XXX | (185%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Starpharma Stock Performance
Starpharma has current market cap of $209M, and enterprise value of $197M.
Market Cap Evolution
Starpharma's stock price is $0.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $197M | $209M | 2.7% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStarpharma Valuation Multiples
Starpharma trades at 20.2x EV/Revenue multiple, and (54.5x) EV/EBITDA.
EV / Revenue (LTM)
Starpharma Financial Valuation Multiples
As of April 18, 2026, Starpharma has market cap of $209M and EV of $197M.
Equity research analysts estimate Starpharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Starpharma has a P/E ratio of (62.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $209M | XXX | $209M | XXX | XXX | XXX |
| EV (current) | $197M | XXX | $197M | XXX | XXX | XXX |
| EV/Revenue | 20.2x | XXX | 56.0x | XXX | XXX | XXX |
| EV/EBITDA | (54.5x) | XXX | (33.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (22.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 22.0x | XXX | 74.6x | XXX | XXX | XXX |
| P/E | (62.1x) | XXX | (32.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (40.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Starpharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Starpharma Margins & Growth Rates
Starpharma's revenue in the last 12 month grew by 65%.
Starpharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Starpharma's rule of 40 is 83% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Starpharma's rule of X is 222% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Starpharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 65% | XXX | 224% | XXX | XXX | XXX |
| EBITDA Margin | (37%) | XXX | (170%) | XXX | XXX | XXX |
| EBITDA Growth | (90%) | XXX | (49%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 83% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 222% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 62% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 56% | XXX | 170% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Starpharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| ProQR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cereno Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| Searle Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Sagimet Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Starpharma M&A Activity
Starpharma acquired XXX companies to date.
Last acquisition by Starpharma was on XXXXXXXX, XXXXX. Starpharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Starpharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStarpharma Investment Activity
Starpharma invested in XXX companies to date.
Starpharma made its latest investment on XXXXXXXX, XXXXX. Starpharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Starpharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Starpharma
| When was Starpharma founded? | Starpharma was founded in 1997. |
| Where is Starpharma headquartered? | Starpharma is headquartered in Australia. |
| How many employees does Starpharma have? | As of today, Starpharma has over 40 employees. |
| Is Starpharma publicly listed? | Yes, Starpharma is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Starpharma? | Starpharma trades under SPL ticker. |
| When did Starpharma go public? | Starpharma went public in 2000. |
| Who are competitors of Starpharma? | Starpharma main competitors are ProQR Therapeutics, Cereno Scientific, Searle Co., Sagimet Biosciences. |
| What is the current market cap of Starpharma? | Starpharma's current market cap is $209M. |
| What is the current revenue of Starpharma? | Starpharma's last 12 months revenue is $10M. |
| What is the current revenue growth of Starpharma? | Starpharma revenue growth (NTM/LTM) is 65%. |
| What is the current EV/Revenue multiple of Starpharma? | Current revenue multiple of Starpharma is 20.2x. |
| Is Starpharma profitable? | No, Starpharma is not profitable. |
| What is the current EBITDA of Starpharma? | Starpharma has negative EBITDA and is not profitable. |
| What is Starpharma's EBITDA margin? | Starpharma's last 12 months EBITDA margin is (37%). |
| What is the current EV/EBITDA multiple of Starpharma? | Current EBITDA multiple of Starpharma is (54.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.